Obigen Pharma (鼎晉生技), Taiwan’s premier innovator specializing in next-generation botulinum toxin therapeutics, convened its Annual General Shareholders' Meeting on May 22, 2026, finalizing a comprehensive restructuring of its Board of Directors. The newly elected board includes Chiang Yung-fong (designated representative of OBI Pharma), Yin Chung-yao (designated representative of Ruentex Development), alongside OBI Pharma representatives Dr. May-June Ma and Chou Pei-fen. The three newly appointed independent directors are Chang Zhen-wu, Liu Yong-fu, and Chen Sung-po.

During the assembly, shareholders approved the 2025 operational reports, audited financial statements, and deficit compensation allocations, while authorizing amendments to the Articles of Incorporation to permit private placements of common stock and/or domestic convertible bonds (CBs).

• Clinical Pivot to Commercialization: Minitron’s flagship asset, OBI-858—a proprietary, long-acting formulation of Botulinum Toxin Type A—successfully finalized patient enrollment for its Phase 3 aesthetic clinical trial with the Taiwan FDA (TFDA) in March 2026. Concurrently, the company is actively advancing its Phase 2 clinical program with the US FDA. This dual regulatory progress marks Obigen Pharma's formal corporate transition from a pure R&D-stage entity into a commercially operational biotechnology enterprise.
• Executive Leadership Alignment: To capitalize on the expanding multi-billion-dollar global medical aesthetics market, the board elected Chiang Yung-fong, Vice Chairman of OBI Pharma, as the new Chairman of Obigen Pharma. Chiang possesses deep institutional lineage within the Ruentex Group (潤泰集團), previously serving as the CEO of RT-Mart and accumulating over 20 years of retail footprint expansion and operational management experience across mainland China. Additionally, global pharmaceutical industry veteran Chang Zhen-wu, who brings 35 years of international drug development experience, was brought in as an independent director.
• Resource Integration Matrix: The corporate reorganization signals continued, deep capitalization support from the OBI Pharma ecosystem while systematically integrating the cross-industry market assets of the Ruentex Group—which spans retail, financial services, real estate, healthcare, and logistics. This collaborative infrastructure is designed to drive Obigen Pharma across three core pillars: clinical acceleration, business model diversification (including cross-industry strategic alliances), and global out-licensing negotiations to capture market share across wider Asian and Western medical aesthetic sectors.

Resource: 鼎晉攜手潤泰力推肉毒桿菌素新藥國際化布局